Repository logo
 
Publication

Comparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Difference

2022Journal article Open access
Simple item page
dc.contributor.authorSousa‐Pinto, B
dc.contributor.authorSchünemann, HJ
dc.contributor.authorSá‐Sousa, A
dc.contributor.authorVieira, RJ
dc.contributor.authorAmaral, R
dc.contributor.authorAnto, JM
dc.contributor.authorKlimek, L
dc.contributor.authorCzarlewski, W
dc.contributor.authorMullol, J
dc.contributor.authorPfaar, O
dc.contributor.authorBedbrook, A
dc.contributor.authorBrussino, L
dc.contributor.authorKvedariene, V
dc.contributor.authorLarenas‐Linnemann, D
dc.contributor.authorOkamoto, Y
dc.contributor.authorVentura, MT
dc.contributor.authorAgache, I
dc.contributor.authorAnsotegui, IJ
dc.contributor.authorBergmann, KC
dc.contributor.authorBosnic‐Anticevich, S
dc.contributor.authorBrozek, J
dc.contributor.authorCanonica, GW
dc.contributor.authorCardona, V
dc.contributor.authorCarreiro‐Martins, P
dc.contributor.authorCasale, T
dc.contributor.authorCecchi, L
dc.contributor.authorChivato, T
dc.contributor.authorChu, DK
dc.contributor.authorCingi, C
dc.contributor.authorCosta, EM
dc.contributor.authorCruz, AA
dc.contributor.authorDel Giacco, S
dc.contributor.authorDevillier, P
dc.contributor.authorEklund, P
dc.contributor.authorFokkens, WJ
dc.contributor.authorGemicioglu, B
dc.contributor.authorHaahtela, T
dc.contributor.authorIvancevich, JC
dc.contributor.authorIspayeva, Z
dc.contributor.authorJutel, M
dc.contributor.authorKuna, P
dc.contributor.authorKaidashev, I
dc.contributor.authorKhaitov, M
dc.contributor.authorKraxner, H
dc.contributor.authorLaune, D
dc.contributor.authorLipworth, B
dc.contributor.authorLouis, R
dc.contributor.authorMakris, M
dc.contributor.authorMonti, R
dc.contributor.authorMorais‐Almeida, M
dc.contributor.authorMösges, R
dc.contributor.authorNiedoszytko, M
dc.contributor.authorPapadopoulos, NG
dc.contributor.authorPatella, V
dc.contributor.authorPham‐Thi, N
dc.contributor.authorRegateiro, FS
dc.contributor.authorReitsma, S
dc.contributor.authorRouadi, PW
dc.contributor.authorSamolinski, B
dc.contributor.authorSheikh, A
dc.contributor.authorSova, M
dc.contributor.authorTodo‐Bom, A
dc.contributor.authorTaborda‐Barata, L
dc.contributor.authorToppila‐Salmi, S
dc.contributor.authorSastre, J
dc.contributor.authorTsiligianni, I
dc.contributor.authorValiulis, A
dc.contributor.authorVandenplas, O
dc.contributor.authorWallace, D
dc.contributor.authorWaserman, S
dc.contributor.authorYorgancioglu, A
dc.contributor.authorZidarn, M
dc.contributor.authorZuberbier, T
dc.contributor.authorFonseca, JA.
dc.contributor.authorBousquet, J
dc.date.accessioned2022-11-03T16:15:45Z
dc.date.available2022-11-03T16:15:45Z
dc.date.issued2022
dc.description.abstractBackground: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., "real-world data"). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods: We assessed the MASK-air® app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80). Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationAllergy. 2022 Oct;77(10):3002-3014pt_PT
dc.identifier.doi10.1111/all.15371pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4261
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWileypt_PT
dc.subjectAllergen immunotherapy;pt_PT
dc.subjectAllergic rhinitispt_PT
dc.subjectCo-medicationpt_PT
dc.subjectMultivariable mixed-effects modelpt_PT
dc.subjectReal-world datapt_PT
dc.subjectHDE ALERpt_PT
dc.titleComparison of Rhinitis Treatments Using MASK-air ® Data and Considering the Minimal Important Differencept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage3014pt_PT
oaire.citation.issue10pt_PT
oaire.citation.startPage3002pt_PT
oaire.citation.titleAllergypt_PT
oaire.citation.volume77pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Allergy 2022_3002.pdf
Size:
1.76 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ALER - Artigos